GOG OPEN PROTOCOLS (as of 9/4/08)

GOG 209: Randomized phase III trial of doxorubicin/cisplatin/paclitaxel and G-CSF versus carboplatin/paclitaxel in patients with stage III, IV, or recurrent endometrial cancer (must not have received prior cytotoxic chemotherapy)
GOG 210: Molecular staging study of endometrial carcinoma (please see back for eligibility criteria)
GOG 224: Randomized, Controlled Phase II Evaluation of Megestrol in Different Dose and Sequence in the Treatment of Endometrial Intraepithelial Neoplasia (EIN) from a Referred Cohort of Atypical Endometrial Hyperplasia (AEH) or EIN
GOG 232C: A Phase II Evaluation of Paclitaxel, Carboplatin, and BSI-201 in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma
GOG 219: Phase III, randomized trial of weekly cisplatin and radiation versus cisplatin and tirapazamine and radiation in stage IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis
GOG 205: Phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva
GOG 187:  Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-line Therapy
GOG 212: Randomized phase III trial of maintenance chemotherapy comparing 12, monthly cycles of single agent paclitaxel or xyotax versus no treatment until documented relapse in women with advanced ovarian or primary peritoneal cancer who achieve a complete clinical response to primary platinum/taxane chemotherapy
GOG 213: Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
GOG 218: Phase III trial of carboplatin and paclitaxel plus placebo versus carboplatin and paclitaxel plus concurrent bevacizumab (NSC #704865, IND #7921) followed by placebo, versus carboplatin and paclitaxel plus concurrent and extended bevacizumab, in women with newly diagnosed, previously untreated, suboptimal advanced stage epithelial ovarian and primary peritoneal cancer
GOG 235: Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy
GOG 136: Acquisition of human gynecologic specimens and serum to be used in studying the causes, diagnosis, prevention, and treatment of cancer
GOG 215: Phase II Randomized Study of the Effect of Zoledronic Acid Versus Observation on Bone Mineral Density of the Lumbar Spine in Women who Elect to Undergo Surgery that Results in Removal of Both Ovaries (women who have already undergone {within 8 weeks} surgery are eligible)

***Pending GOG 238, GOG 207, Precision ChemoFx***

For more information on the GOG trials, please contact:

Jasmine Taylor
Research Data Manager
820 South Wood Street, Rm 265, MC 808
Chicago, IL 60612
Phone (312) 355-3614
Fax (312) 355-5656
E-Mail jdaqui1@uic.edu